Theravance Biopharma Inc. (NASDAQ:TBPH) was downgraded by investment analysts at TheStreet from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

A number of other analysts also recently issued reports on the company. Bank of America Corp. downgraded Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Robert W. Baird downgraded Theravance Biopharma from a “neutral” rating to an “underperform” rating and lifted their price target for the company from $19.00 to $24.00 in a research report on Wednesday, October 12th. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, October 14th. Guggenheim reiterated a “positive” rating and set a $40.00 price target on shares of Theravance Biopharma in a research report on Monday, September 19th. Finally, Leerink Swann reiterated a “buy” rating and set a $31.00 price target on shares of Theravance Biopharma in a research report on Tuesday, August 9th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $36.83.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Shares of Theravance Biopharma (NASDAQ:TBPH) opened at 31.96 on Thursday. The company’s market capitalization is $1.66 billion. Theravance Biopharma has a one year low of $12.87 and a one year high of $38.92. The company has a 50-day moving average price of $31.67 and a 200 day moving average price of $26.79.

In other Theravance Biopharma news, SVP Brett K. Haumann sold 4,491 shares of Theravance Biopharma stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $27.99, for a total value of $125,703.09. Following the transaction, the senior vice president now directly owns 188,293 shares of the company’s stock, valued at approximately $5,270,321.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in TBPH. FMR LLC boosted its position in shares of Theravance Biopharma by 70.8% in the second quarter. FMR LLC now owns 3,278,215 shares of the biopharmaceutical company’s stock worth $74,383,000 after buying an additional 1,358,912 shares during the period. Vanguard Group Inc. boosted its position in shares of Theravance Biopharma by 25.5% in the second quarter. Vanguard Group Inc. now owns 2,451,566 shares of the biopharmaceutical company’s stock worth $55,626,000 after buying an additional 497,350 shares during the period. BlackRock Fund Advisors boosted its position in shares of Theravance Biopharma by 2.7% in the third quarter. BlackRock Fund Advisors now owns 1,833,096 shares of the biopharmaceutical company’s stock worth $66,431,000 after buying an additional 47,389 shares during the period. First Manhattan Co. boosted its position in shares of Theravance Biopharma by 2.2% in the third quarter. First Manhattan Co. now owns 1,043,733 shares of the biopharmaceutical company’s stock worth $37,824,000 after buying an additional 22,500 shares during the period. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Theravance Biopharma by 9.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 879,952 shares of the biopharmaceutical company’s stock worth $31,889,000 after buying an additional 73,601 shares during the period. 65.02% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

5 Day Chart for NASDAQ:TBPH

Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.